| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.2 | 0.0004 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.19 | 0.001 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | 0.096 | 0.004 |
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | 0.084 | 0.01 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.077 | 0.01 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.14 | 0.02 |